Azilect Related Published Studies
Well-designed clinical trials related to Azilect (Rasagiline)
A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. [2011.05]
Clinical pharmacology tyramine challenge study to determine the selectivity of the monoamine oxidase type B (MAO-B) inhibitor rasagiline. [2010.12]
Long-term efficacy of rasagiline in early Parkinson's disease. [2010.06]
The role of rasagiline in the treatment of Parkinson's disease. [2010.05.25]
Clinical pharmacology tyramine challenge study to determine the selectivity of
the monoamine oxidase type B (MAO-B) inhibitor rasagiline. [2010]
A double-blind, delayed-start trial of rasagiline in Parkinson's disease. [2009.09.24]
Role of rasagiline in treating Parkinson's disease: Effect on disease progression. [2009.08]
Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. [2009.03.15]
A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics. [2008.11.15]
A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): Rationale, design, and baseline characteristics. [2008.10.19]
Transtelephonic home blood pressure to assess the monoamine oxidase-B inhibitor rasagiline in Parkinson disease. [2008.09]
Transtelephonic Home Blood Pressure to Assess the Monoamine Oxidase-B Inhibitor Rasagiline in Parkinson Disease. [2008.08.04]
Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms. [2006.10.25]
Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline. [2006.10]
Rasagiline improves quality of life in patients with early Parkinson's disease. [2006.05]
Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. [2005.03.12]
Tolerability, safety, pharmacodynamics, and pharmacokinetics of rasagiline: a potent, selective, and irreversible monoamine oxidase type B inhibitor. [2004.10]
Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients. [2004.08]
Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa. [2000.11]
Well-designed clinical trials possibly related to Azilect (Rasagiline)
The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease. [2011.10]
Milestones in Parkinson's disease therapeutics. [2011.05]
Determination of minimal clinically important change in early and advanced Parkinson's disease. [2011.04]
Determination of minimal clinically important change in early and advanced
Parkinson's disease. [2011]
Validation of the freezing of gait questionnaire in patients with Parkinson's disease. [2009.04.15]
Impact of newer pharmacological treatments on quality of life in patients with Parkinson's disease. [2008]
Monamine oxidase inhibitors: current and emerging agents for Parkinson disease. [2007.05]
Test-retest reliability of the unified Parkinson's disease rating scale in patients with early Parkinson's disease: results from a multicenter clinical trial. [2002.07]
Other research related to Azilect (Rasagiline)
Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson's disease. [2011.12]
Rasagiline: Time to Onset of Antiparkinson Effect is Similar When Used as a Monotherapy or Adjunct Treatment. [2011.11]
Efficacy, safety and tolerability of rasagiline as adjunctive therapy in elderly patients with Parkinson's disease. [2011.08.05]
Safety of rasagiline for the treatment of Parkinson's disease. [2011.07]
The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: A randomized, double-blind, placebo-controlled, multicenter study. [2011.04.15]
Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in
Parkinson's disease. [2011]
The effects of rasagiline on cognitive deficits in Parkinson's disease patients
without dementia: a randomized, double-blind, placebo-controlled, multicenter
study. [2011]
Site-activated chelators derived from anti-Parkinson drug rasagiline as a potential safer and more effective approach to the treatment of Alzheimer's disease. [2010.12]
[Rasagiline: effectiveness and protection in Parkinson's disease]. [2010.11.01]
Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity. [2010.11]
Efficacy and tolerability of rasagiline in daily clinical use--a post-marketing observational study in patients with Parkinson's disease. [2010.09]
What Is the Clinical Significance of the Findings from the Delayed-Start Trial of Rasagiline in Parkinson's Disease? [2010.07.27]
Clinical Pharmacology Tyramine Challenge Study to Determine the Selectivity of the Monoamine Oxidase Type B (MAO-B) Inhibitor Rasagiline. [2010.05.05]
Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction? [2010.04.06]
The neuroprotective mechanism of 1-(R)-aminoindan, the major metabolite of the anti-parkinsonian drug rasagiline. [2010.03]
Low dosage of rasagiline and epigallocatechin gallate synergistically restored the nigrostriatal axis in MPTP-induced parkinsonism. [2010]
[Rasagiline is not for all Parkinson disease patients: the ADAGIO study]. [2010]
The role of rasagiline in the treatment of Parkinson's disease. [2010]
RimabotulinumtoxinB effects on pain associated with cervical dystonia: results of
placebo and comparator-controlled studies. [2010]
Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no
satisfaction? [2010]
Lack of clinically significant interactions between concomitantly administered rasagiline and escitalopram. [2009.11.13]
Investigation of oral selegiline and rasagiline administration on QT interval in conscious rabbits. [2009.03]
Neuroprotection by rasagiline in thiamine deficient rats. [2009.02.23]
Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer's disease drugs. [2009.01]
Cost effectiveness of rasagiline and pramipexole as treatment strategies in early Parkinson's disease in the UK setting: an economic Markov model evaluation. [2009]
Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. [2008.12.11]
[Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment] [2008.10]
Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopaminergic degeneration. [2008.06]
[Rasagiline in Parkinson's disease] [2008.05]
Rasagiline is neuroprotective in a transgenic model of multiple system atrophy. [2008.04]
Rasagiline improves freezing in a patient with primary progressive freezing gait. [2008.02.15]
Rasagiline in treatment of Parkinson's disease. [2008.02]
Differential behavioral syndrome evoked in the rats after multiple doses of SSRI fluoxetine with selective MAO inhibitors rasagiline or selegiline. [2008]
Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapy. [2007.12]
Rasagiline promotes regeneration of substantia nigra dopaminergic neurons in post-MPTP-induced Parkinsonism via activation of tyrosine kinase receptor signaling pathway. [2007.10]
Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's Disease. [2007.09]
Rasagiline is neuroprotective in an experimental model of brain ischemia in the rat. [2007]
Rasagiline: a review of its use in the management of Parkinson's disease. [2007]
Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease. [2006.12]
The path from anti Parkinson drug selegiline and rasagiline to multifunctional neuroprotective anti Alzheimer drugs ladostigil and m30. [2006.12]
Clinical trials with rasagiline: evidence for short-term and long-term effects. [2006.05.23]
Rasagiline: A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease. [2006.05.15]
Safety of rasagiline in elderly patients with Parkinson disease. [2006.05.09]
Cost-utility model of rasagiline in the treatment of advanced Parkinson's disease in Finland. [2006.04]
Rasagiline: defining the role of a novel therapy in the treatment of Parkinson's disease. [2006.02]
The use of rasagiline in Parkinson's disease. [2006]
Rasagiline in the pharmacotherapy of Parkinson's disease--a review. [2005.10]
Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease. [2005.08]
Neuropharmacological, neuroprotective and amyloid precursor processing properties of selective MAO-B inhibitor antiparkinsonian drug, rasagiline. [2005.06]
Neuroprotection by rasagiline: a new therapeutic approach to Parkinson's disease? [2005.06]
Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives. [2005.04]
Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition. [2005.01.01]
Rasagiline. [2005]
Rasagiline alone and in combination with riluzole prolongs survival in an ALS mouse model. [2004.09]
Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease. [2004.06]
Amyloid processing and signal transduction properties of antiparkinson-antialzheimer neuroprotective drugs rasagiline and TV3326. [2003.05]
Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan. [2002.08]
Rasagiline. Teva Pharmaceutical. [2002.05]
The anti-Parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells. [2002.04]
Rat striatal monoamine oxidase-B inhibition by l-deprenyl and rasagiline: its relationship to 2-phenylethylamine-induced stereotypy and Parkinson's disease. [2002.03]
Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol. [2001.08]
The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo. [2001.06]
Neuroprotective effects of novel cholinesterase inhibitors derived from rasagiline as potential anti-Alzheimer drugs. [2001.06]
Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse. [1999.02.05]
Studies with rasagiline, a MAO-B inhibitor, in experimental focal ischemia in the rat. [1999]
Other possibly related research studies
Clinical trials for neuroprotection in Parkinson's disease: overcoming angst and futility? [2007.08]
The kinetics of inhibition of human acetylcholinesterase and butyrylcholinesterase by two series of novel carbamates. [2007.06]
L-methamphetamine and selective MAO inhibitors decrease morphine-reinforced and non-reinforced behavior in rats; Insights towards selegiline's mechanism of action. [2006.12]
Concerning neuroprotective therapy for Parkinson's disease. [2006]
Rationale for considering that propargylamines might be neuroprotective in Parkinson's disease. [2006.05.23]
Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness. [2006.01]
Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors. [2005.11]
Present and future drug treatment for Parkinson's disease. [2005.11]
Parkinson's disease. Diagnosis and the initiation of therapy. [2005.06]
|
